Patents Assigned to NEPSONE EHF
  • Methods of treating inflammatory skin disorders
    Patent number: 11517612
    Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: December 6, 2022
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Methods of treating inflammatory skin disorders
    Patent number: 11433119
    Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: September 6, 2022
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Methods of treating inflammatory skin disorders
    Patent number: 11266718
    Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: May 30, 2020
    Date of Patent: March 8, 2022
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson
  • Use of CGRP antagonist compounds for treatment of psoriasis
    Patent number: 10668132
    Abstract: A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: June 2, 2020
    Assignee: NEPSONE EHF
    Inventor: Birkir Sveinsson